PJI after THA may be associated with similar mortality rates vs. common cancers
Click Here to Manage Email Alerts
Key takeaways:
- Periprosthetic joint infection was associated with similar mortality rates vs. breast and prostate cancer.
- Patients with periprosthetic joint infection had an 11% mortality rate at 40.3 months.
Presented results showed patients with periprosthetic joint infection after total hip arthroplasty may have similar rates of mortality compared with those of common cancers such as breast cancer and prostate cancer.
At the Musculoskeletal Infection Society Annual Meeting, Anabelle T. Visperas, PhD, a staff scientist at the Cleveland Clinic in Ohio, presented results from a literature review of 20 studies with 19,917 patients who had PJI after THA.
Visperas and colleagues assessed the overall incidence of mortality for patients with PJI, as well as incidence of mortality associated with type of treatment such as debridement, antibiotics, and implant retention (DAIR), 1-stage revision and 2-stage revision.
Overall, Visperas and colleagues found an 11% mortality rate at a mean follow-up of 40.3 months for patients with PJI after THA. They found the pooled incidence of mortality was 1.1% at 3 months, 3.7% at 1 year and 1% at 2 years.
Visperas and colleagues found patients who underwent DAIR had a mortality rate of 7.8%, whereas patients who underwent 1-stage and 2-stage revision had mortality rates of 1.6% and 9.2%, respectively. However, Visperas noted that mortality associated with DAIR was reported in one study and mortality associated with 1-stage revision was reported in two studies.
“We see about [a] 2% mortality rate at 5 years with prostate cancer [and] about [a] 10% mortality rate with breast cancer, and in the study, we see about an 11% mortality rate with PJI,” Visperas said.
Visperas concluded a multidisciplinary approach may be best to treat patients with PJI after THA.
Collapse
Ramos MS, et al. Paper 1244. Presented at: Musculoskeletal Infection Society Annual Meeting; Aug. 2-3, 2024; Durham, North Carolina (hybrid meeting).
Click Here to Manage Email Alerts